These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38244586)
1. α-Hederin promotes ferroptosis and reverses cisplatin chemoresistance in non-small cell lung cancer. Han S; Yang X; Zhuang J; Zhou Q; Wang J; Ru L; Niu F; Mao W Aging (Albany NY); 2024 Jan; 16(2):1298-1317. PubMed ID: 38244586 [TBL] [Abstract][Full Text] [Related]
2. Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p/miR-615-3p axis. Han B; Liu Y; Zhang Q; Liang L J Proteomics; 2023 Mar; 274():104777. PubMed ID: 36427803 [TBL] [Abstract][Full Text] [Related]
3. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis. Song Z; Jia G; Ma P; Cang S Life Sci; 2021 Jul; 276():119399. PubMed ID: 33781830 [TBL] [Abstract][Full Text] [Related]
4. Regulatory mechanism of α-hederin upon cisplatin sensibility in NSCLC at safe dose by destroying GSS/GSH/GPX2 axis-mediated glutathione oxidation-reduction system. Wu Y; Wang D; Lou Y; Liu X; Huang P; Jin M; Huang G Biomed Pharmacother; 2022 Jun; 150():112927. PubMed ID: 35398749 [TBL] [Abstract][Full Text] [Related]
5. LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis. Chen H; Wang L; Liu J; Wan Z; Zhou L; Liao H; Wan R Cancer Biol Ther; 2023 Dec; 24(1):2223377. PubMed ID: 37370246 [TBL] [Abstract][Full Text] [Related]
6. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549. Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669 [TBL] [Abstract][Full Text] [Related]
7. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9. Liu B; Wang R; Liu H Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989 [TBL] [Abstract][Full Text] [Related]
8. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis. Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of METTL14-mediated m Gong S; Wang S; Shao M J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154 [TBL] [Abstract][Full Text] [Related]
10. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells. Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943 [TBL] [Abstract][Full Text] [Related]
11. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis. Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072 [TBL] [Abstract][Full Text] [Related]
12. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells. Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212 [TBL] [Abstract][Full Text] [Related]
13. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342 [TBL] [Abstract][Full Text] [Related]
14. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Xiao XH; He SY Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431 [TBL] [Abstract][Full Text] [Related]
15. LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress. Ma P; Han W; Meng C; Tan X; Liu P; Dong L Anal Cell Pathol (Amst); 2022; 2022():6100176. PubMed ID: 36311891 [TBL] [Abstract][Full Text] [Related]
16. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2. Liu Y; Zhang Y; Li Q; Xu R; Huang N Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447 [TBL] [Abstract][Full Text] [Related]
17. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114 [TBL] [Abstract][Full Text] [Related]
18. Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497-5p/mTOR. Hou Z; Wang Y; Xia N; Lv T; Yuan X; Song Y Cancer Sci; 2021 Jan; 112(1):275-286. PubMed ID: 33179318 [TBL] [Abstract][Full Text] [Related]
19. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948 [TBL] [Abstract][Full Text] [Related]
20. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Jiang P; Wu X; Wang X; Huang W; Feng Q Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]